[go: up one dir, main page]

0% found this document useful (0 votes)
144 views118 pages

Validation of Dry Heat Processes PDA TR-3

Download as pdf or txt
Download as pdf or txt
Download as pdf or txt
You are on page 1/ 118

9/18/2019

Validation of Dry Heat


Processes Used for
Depyrogenation
And Sterilization

Technical Report No. 3


(2013 Revision)
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association

Task Force Members


• Bruce Bear, Bear Consulting • Brian Jordan, Valsource,
Services LLC
• Stewart Davenport, Pfizer, • Peter Lee, Mattell Inc.
Inc.
• Hans Melgaard, Despatch
• Mike Davies, GlaxoSmithKline Industries
Pharmaceuticals
• Christian Supina, Baxter
• Steve Folio, Althea
Technologies Healthcare Corporation

• Jill Giulianelli, West-Ward • Rita Welser, Boehringer


Pharmaceuticals Ingelheim
• Deborah Havlik, Hospira, Inc. • Robyn Wong, Celgene
Corporation

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 2

1
9/18/2019

Instructor Bio
Deborah Havlik
• DAHavlik Consulting, Greater Chicago Area
• Director, Pharmaceutical Microbiology, R&D,
Hospira, a Pfizer company
• Contract Micro Lab and Ethylene Oxide
Sterilization
• Medical Device Industry, Class III manufacturer
• PDA Task Force
• Convenor of ISO WG 14, Dry Heat; Microbiological
Methods
• AAMI: Radiation, Ethylene Oxide, Dry Heat,
Microbiological Methods, Aseptic Processing, BIs
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 3

Class Introductions

• Name
• Company
• Position/Title
• Student objectives/expectations
• Instructor’s learning objectives

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 4

2
9/18/2019

Announcements

• Attendance list
• Course/Instructor evaluations
• ACPE Form
• Disclosure

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 5

Course Schedule

• 8:30 a.m. Class Begins


• 10:00 – 10:15 a.m. Morning Break
• 12 noon – 1:00 p.m. Lunch (provided)
• 2:30 – 2:45 p.m. Afternoon Break
• 3:45 – 4:00 p.m. Class Ends

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 6

3
9/18/2019

Course Outline

• Introduction and Scope


• Glossary of Terms
• The Science of Dry Heat Inactivation and
Sterilization
• Equipment Design
• Equipment Verification
• Process Development
• Performance Qualification
• Ongoing Process Control
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 7

Section 1

Introduction
and Scope

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 8

4
9/18/2019

Introduction

• Update of PDA’s Technical Report No. 3, Validation of


Dry Heat Sterilization Processes used for Sterilization
and Depyrogenation (issued in 1982)
• Focus
– Microbiology and engineering qualification of dry heat
sterilization and depyrogenation processes
– General approach to sterilization and depyrogenation science
in batch and continuous sterilizers (ovens and tunnels)

Validation: A documented program that provides a high level of scientific


assurance that a manufacturing process will reliably produce acceptable
product. The proof of validation is obtained through rational experimental
design and the evaluation of data, preferably beginning from the process
development phase and continuing through the commercial production phase
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 9

Scope (1)

• Provides information to the manufacturers of


pharmaceutical products for validating dry heat
depyrogenation and sterilization processes
• Concepts and methods presented in this
technical report are points to consider during the
validation of dry heat processes
– Not intended to be a regulatory standard
– Other technically equivalent methods may exist and
may be used if they can be supported by sound
scientific methods

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 10

10

5
9/18/2019

Scope (2)
Use of biological indicators and endotoxin indicators

Points to Equipment design


consider:
Equipment verification

Process development

Performance qualification for new systems

Development and validation of processes for existing


systems.
Ongoing maintenance of the validated process.

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 11

11

Scope

• Process development in both ovens and tunnels


focusing on:
– Load type
– Loading patterns
– Temperature profiles for depyrogenation and sterilization
• Background sections specific to dry heat
processes
• Applicable to the following:
– Forced hot air dry heat batch processes (chambers)
– Continuous processes (tunnels)
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 12

12

6
9/18/2019

Out of Scope

• Dry heat processes used for the following:


– Sterilization of oil based and oil products
– Fixed processing streams
– Processes using infrared and microwave heating
media

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 13

13

Section 2:

Glossary of Terms

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 14

14

7
9/18/2019

Glossary of Terms

• Current FDA, ICH, and other regulatory definitions are used


except when more clarity is added by the Task Force
• Regulatory guidelines offer other definitions that may be
considered
• Variations in the use of some terms may differ from company
to company, and some may be subject to change in the
future
• However, the terms used in a validation program must be
clearly defined and well understood within the company
• Clearly defined in internal Standard Operating Procedures
(SOPs), standards, and in regulatory filings

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 15

15

Section 3:

The Science of Dry Heat


Depyrogenation
and Sterilization

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 16

16

8
9/18/2019

Dry Heat Processes

Sterilization

Dry Heat
OR
Processes
Depyrogenation
and sterilization

The purpose of process will dictate the validation


approach

Depyrogenation: The destruction or removal of bacterial endotoxins.


Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 17

17

Dry Heat Depyrogenation (1)

• One primary method used to inactivate and remove


bacterial endotoxins by thermal destruction
• Ovens or tunnels used for depyrogenation of heat
resistant materials
– Glassware, metal equipment, instruments, containers, and
heat stable chemicals
• Limulus Amebocyte Lysate (LAL) assay provides a
means of assessing the performance of dry heat
endotoxin inactivation on a quantitative basis

Bacterial Endotoxin: Endotoxins are fever producing substances commonly


found in the cell wall of certain Gram negative bacteria.
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 18

18

9
9/18/2019

Dry Heat Depyrogenation (2)

Destruction of LPS
“Whereas many • 250 C for 30 minutes
sterilization
processes are
predictable, many
depyrogenation
procedures are Literature references
purely empirical.” • Lack of agreement in
temperature and times
Kevin Williams, Eli Lilly & • Many conditions affect
Co. depyrogenation
parameters

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 19

19

Dry Heat Depyrogenation (3)

• Temperature and exposure time


– Validate appropriately

– Demonstrate adequate and reproducible level of endotoxin


reduction when operated routinely within established
tolerances

• Include an endotoxin challenge, where necessary, as


an integral part of the validation program
– Example: by inoculating one or more of the articles to be
treated with 1000 or more USP Endotoxin Units (EU) of
bacterial endotoxin

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 20

20

10
9/18/2019

Dry Heat Depyrogenation:


Inactivation of Endotoxin

Commonly used for materials that can


withstand high temperatures for a period of
time using incineration in order to achieve
Bacterial Endotoxin inactivation

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 21

21

Dry Heat Depyrogenation:


Heat Lethality of Incineration
Anticipate
Provides large
microbial
reductions well in
margin of safety with
excess of 10100
regard to sterility
• B. atrophaeus (formerly Therefore
Bacillus subtilis var niger)
Process lethality
spores have D values
of only a few seconds
can be defined
at temperatures used on the basis of
for depyrogenation endotoxin
inactivation

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 22

22

11
9/18/2019

Dry Heat Depyrogenation:


Validation and Practice

Validation
• Dry heat endotoxin reduction studies are always
conducted rather than microbial inactivation studies
• Inactivation rate of endotoxin is slower than the
inactivation rate of the biological indicator used (e.g.,
spores of Bacillus atropheus)

In Practice
• The reduction of endotoxin challenge by three or more
logs will result in a process that also achieves the
probability of non-sterility substantially less than 10-6

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 23

23

Dry Heat Depyrogenation:


Inactivation of Endotoxin

Greater than
Inactivation
of Endotoxin
= or = 3 log of
reduction

Assumption: the depyrogenation process will inactivate


bacterial endotoxins that could be presented by any given
component manufacturing process.

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 24

24

12
9/18/2019

Review Question #1

Dry heat depyrogenation is the only method


to inactivate and remove bacterial
endotoxin by thermal destruction
• True
• False

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 25

25

Review Question #2

During validation, dry heat endotoxin


reduction studies are always conducted
rather than microbial inactivation studies
because:
A. The inactivation rate of the endotoxin is faster than
the inactivation rate of the biological indicator
B. The inactivation rate of the endotoxin is slower than
the inactivation rate of the biological indicator

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 26

26

13
9/18/2019

Dry Heat Depyrogenation:


Reduction of Endotoxin
• Thermal incineration
dependent on factors that
Most accurate
affect heat distribution in a assessment of
chamber or tunnel reduction:
– Mass and configuration of the Endotoxin Indicator
least prone to variables
load
associated with
• Chemical nature of endotoxin recovery
components impact techniques
recovery of endotoxin only
– Not reduction

Endotoxin Indicators: An article challenge vial of endotoxin (or a carrier


spiked with endotoxin) designed for use in depyrogenation studies
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 27

27

Glossary of Terms:
Endotoxin Indicator (EI)
An article challenge vial of endotoxin (or a
carrier spiked with endotoxin) designed for
use in depyrogenation studies.

Image courtesy of rapidmicrobiology.com

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 28

28

14
9/18/2019

Endotoxin Indicator (EI)


for Depyrogenation
• The endotoxin (a purified lipopolysaccaride) is validated
for use in or on an Endotoxin Indicator
• Carrier is made from a material appropriate for the
intended depyrogenation processes to which it will
be subjected
• The endotoxin on a carrier is added at a
concentration sufficient to allow recovery of a
minimum of 1000 USP Endotoxin Units/carrier
• The Endotoxin Indicator would allow for accurate
indication of at least a 3-log reduction in USP
Endotoxin Units during depyrogenation process
challenges
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 29

29

Endotoxin Indicators

• Determinants for endotoxin reduction


– Exposure time
– Temperature
• Variables that may affect endotoxin recovery from
suitable carriers or items may include:
– Formulation of the endotoxin
– Surface type, composition and configuration of carrier
– Inoculum (spike) concentration
– Method of inoculation and drying of endotoxin
– Stability and storage of inoculated carriers or items

A detailed guideline for preparing and recovering endotoxin challenges has been published.
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 30

30

15
9/18/2019

Selecting a Carrier for


Depyrogenation Studies

Two approaches

Carrier Selection Commercial EI

• Inoculate carrier • Heat resistant


• Same chemical • Easily vortexed
and physical
properties

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 31

31

Preparation and Inoculation

Washing/Rinsing
• Water for Bacterial
Endotoxin Testing (BET) Inoculation (spiking)
• Water for Injection (WFI) • High potency endotoxin
• Minimize intrinsic • Small volume
contamination resulting • Not less than 1,000
in false positives International Units (IU)
units
• One International Unit
(IU) = one Endotoxin
Unit (EU)

Note: the level of endotoxin with which to inoculate a carrier is somewhat controversial. Purified endotoxin, which is
used in depyrogenation studies, binds more thoroughly to the carrier surface and is more difficult to recover than
natural endotoxin
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 32

32

16
9/18/2019

Bacterial Endotoxin vs LPS

Lipopolysaccharide

Ultrastructure
Of Gram –ve
Bacterial Cell
Wall

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association

33

Glossary of Terms:
Water for Bacterial Endotoxin Test (BET)

Image courtesy of osawaterworks.com

Sterile Water for Injection or


other water that shows no
reaction with the specific
bacterial endotoxin test
reagent with which it is to be
used, at the limit of
sensitivity of such reagent.

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 34

34

17
9/18/2019

EI Fixation Methods

• Air drying the endotoxin challenge


solution to the sample surface is
recommended
– Representative of how endotoxins are
naturally affixed to items
• Drying EIs under an ambient laminar
flow hood is commonly conducted
– However, studies have demonstrated
differences in endotoxin recovery
depending on the type of glass and the
method of fixation
• Lyophilization
• Vacuum drying

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 35

35

Sample Processing (1)

Follow standard procedure and


document process of Endotoxin
Indicator samples
Include control samples such as
negative and positive controls in dry
heat depyrogenation studies
Set aside additional inoculated items
to serve as unprocessed endotoxin
indicator positive controls

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 36

36

18
9/18/2019

Sample Processing (2)

• Positive controls should be handled


in the same manner as the items to
be depyrogenated
– To evaluate the amount of recoverable
endotoxin and calculate log reduction

Image courtesy of abstracts.aapspharmaceutica.com


• Items that have not been inoculated
should also be set aside to serve as
a negative control

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 37

37

Review Question #3

What determines endotoxin reduction? (Select


all that apply)
A. Formulation of the endotoxin
B. Surface type, composition, and configuration
C. Inoculum concentration
D. Exposure time and temperature

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 38

38

19
9/18/2019

Review Question #4

Which variables may affect endotoxin recovery?


(Select all that apply)
A. Method of inoculation and drying of endotoxin
B. Stability and storage of inoculated carriers or
items
C. Formulation of the endotoxin
D. Surface type, composition and configuration of
carrier
E. Exposure time and temperature

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 39

39

Recovery

• The final testing for recovery of endotoxin spike


after treatment will demonstrate whether or not the
quantity of spiked endotoxin was reduced by 3 logs
• Studies demonstrating endotoxin recovery, using
EIs with different surface types, have concluded
that a combination of vortexing and sonicating
improves recovery
– For inoculated surfaces that are not amenable to vortex
mixing or sonication, a previously screened surface active
solution may facilitate the physical removal of endotoxin

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 40

40

20
9/18/2019

Glossary of Terms:
Bacterial Endotoxin Test (BET)

Assay for measuring active endotoxin by combining a liquid


test sample with Limulus amebocyte lysate (LAL) reagent
and measuring the resulting proportional reaction via visual,
turbidimetric, chromogenic, or other validated means of
detection.

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 41

41

Recovery: BET Method/Analyses

• Allow endotoxin recovery and quantification of at least a three log


reduction of the EI
– Example:
EI spike = approx. 5000

LAL Reagent w/at least


IU/component

0.125 IU/ml in sensitivity


Gel-clot assay
conducted Photometric assay has a
suitable standard curve
range such as 0.1-to-10
IU/mL or equivalent

• Conduct all BET analyses of positive controls (unprocessed EIs) and


recoveries from processed components using validated test methods
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 42

42

21
9/18/2019

Result Interpretation/Endotoxin Log


Reduction Calculations

The amount of recoverable endotoxin assayed from the


unprocessed positive control should demonstrate a
3-log reduction of the challenged items.

Depyrogenation
Inactivation of
process will
endotoxin achieves May
Assume sufficiently inactivate
greater than or equal to
endogenous
3 logs of reduction
endotoxins that could
be present

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 43

43

Equation 3.2.4-1

Provides a calculation to determine the log


reduction of an endotoxin indicator
ELR = Log IU0 – Log IUf

IU0 = Average
ELR = Endotoxin recovered positive IUf = Recovered
Log Reduction control endotoxin spike concentration
concentration after exposure
(unprocessed)

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 44

44

22
9/18/2019

Example of Equation 3.2.4-1

Log 1225 – Log 0.5 = 3.1 - (-0.3) = 3.4

Average recovered
positive control Test indicators after Endotoxin log
endotoxin indicator heat treatment reduction

• Highly unlikely that an overkill dry heat cycle would yield


detectable endotoxin in extracts from undiluted exposed EIs
• When endotoxin is undetectable, IUf is the sensitivity of the BET
method
• Such as the labeled sensitivity of a gel-clot reagent or the lowest
endotoxin concentration of a photometric standard curve

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 45

45

Glassware Depyrogenation
• Depyrogenation by washing, rinsing and the
sterilization process is as effective as dry heat
depyrogenation and is cost effective
• Manufacturing process for glass excludes the
potential for bioburden and endotoxin contamination
– Promptly packaged after production in a cleanroom
environment
– Subjected to shrink-wrap for delivery and storage

• Risk of contamination due to exposure to bioburden


is highly unlikely during the handling, packing and
shipping of glass containers during processing and Image courtesy of triforest.com

post cleaning
Note: Not all aspects of this TR are applicable to glassware or other containers that
are used to package products destined for terminal sterilization.
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 46

46

23
9/18/2019

Glassware Depyrogenation

• For products that are aseptically processed and


terminally sterilized, guides exist to ensure glass
is pyrogen-free through depyrogenation
• The rationale as to why terminally sterilized glass
containers may not need to be depyrogenated is
due to the low risk of bacterial endotoxins
contamination from the glass containers
manufacturing process, which can include
temperatures of 815.6°C to 982.2°C (able to
destroy bacterial endotoxins)

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 47

47

Quality Risk Management

• Implement a quality risk management


program to ensure patient safety
throughout the pharmaceutical
manufacturing process that includes
glassware
• Conduct a formal risk assessment of the
shipping, handling and storage of glass
containers using recognized tools (e.g.,
FMEA, HACCP)
– Determine areas of potential endotoxin
contamination with recommended mitigation
and post mitigation review

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 48

48

24
9/18/2019

Assessment Considerations

Packaging to
Quality audit prevent
Handling and
of glass microbial and
shipping
manufacturer endotoxin
contamination

Storage
Storage conditions
conditions prior to and
prior to following
packaging shipping

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 49

49

Steps to Mitigate Risk (1)


May Include:

Environmental
controls to
Inadvertent in- protect
transit damage glassware once
affecting packed and/or
Inspection of washed
shipping integrity of
containers upon shipping
receipt for water container
damage

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 50

50

25
9/18/2019

Steps to Mitigate Risk (2)


May Include:
Bacterial endotoxin
testing of each
batch of finished
Daily testing of WFI sterile product
for bacterial
endotoxins and
Control of the rinse microbial counts not
or wash water step to exceed limits that
prior to filling would elicit a
through quality of pyrogenic response
water used (WFI
recommended)

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 51

51

Review Question #5

Which assessment factors should be


considered when implementing a quality risk
management program? (select all that apply)
A. Quality audit of glass manufacturer
B. Storage conditions prior to packaging
C. Packaging to prevent microbial and endotoxin
contamination
D. Storage conditions prior to and following
shipping
E. All of the above
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 52

52

26
9/18/2019

Review Question #6

It cannot be assumed that the


depyrogenation process will inactivate
bacterial edotoxins present in any
component even if the inactivation of
endotoxin achieved greater than or equal to
3 logs of reduction
A. True
B. False

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 53

53

Dry Heat Sterilization

Slow-acting
sterilizing
agent

Higher
temperatures

Longer
Image courtesy of spaulding-rogers.com exposure
times

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 54

54

27
9/18/2019

Glossary of Terms:
Sterilization Process and Heat

• A process used to render a


Sterilization
Process: product free of viable organisms
with a specified probability

• Energy that is transferred as a


result of a temperature difference
Heat:
between an object and its
surroundings

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 55

55

Dry Heat Sterilization:


Ovens or Tunnels
• Heated filtered air distributed
uniformly throughout the
chamber by:
– Convection
– Thermal radiation Image courtesy of rpdinc.com

• Blower system and devices for:


– Sensing
– Monitoring
– Controlling the operating
parameters
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 56

56

28
9/18/2019

Sterilization

Rate of Temperature
microbiological
destruction Uniformity of the heating medium
influenced by:

Conductivity of the containers and/or


equipment
Accessibility of the device or item fluid
pathway
Physiological state of product bioburden

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 57

57

Sterilization:
Mechanisms of Inactivation (1)
• Typical dry heat temperatures are greater
than or equal to 160°C
– However processes at significantly lower
temperatures have been developed and
validated
• Dry heat inactivates microorganisms
primarily by oxidizing organic compounds

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 58

58

29
9/18/2019

Mechanisms of Inactivation (2)

• Sub-lethal dry heat


temperatures induce
mutations in B. atrophaeus
spores
Image courtesy of llnl.gov

• Primary factors affecting inactivation in


microorganisms include:

Water
Temperature Time
content

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 59

59

Mechanisms of Inactivation (3)


• The death of a homogeneous culture of
microorganisms exposed to constant lethal stress
(survivor curve) has been shown empirically to
follow first-order kinetics
• The rate of microbial lethality is a function of:
– Thermal resistance of the microorganism
– Lethal stress
• Rate of microbial lethality is independent of the
number of microorganisms in the challenge
Survivor Curve: Graphical representation of the inactivation of a population of
microorganisms with increasing exposure to a microbicidal agent under stated
conditions
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 60

60

30
9/18/2019

The Survivor Curve: Equation 3.3.1-1


Log NF = −F(T,z)/DT + Log N0
NF = Number of
DT = Thermal
microorganisms
resistance value, in
after exposure
minutes, of the
of F equivalent
microorganism at a
minutes
specific
temperature
F(T,z) = Equivalent lethality Note: This specific temperature
must be the same as the
of a process calculated as reference temperature used for
minutes at a reference calculating F-value
temperature (T), using a
defined temperature N0 = Number of
coefficient (z) microorganisms
prior to exposure
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 61

61

Glossary of Terms:
F-Value and z-value
F-Value (Lethality Factor):

• A measurement of process effectiveness


• F is the calculated equivalent lethality (using a
specified z-value) for a sterilization process, in terms
of minutes at a reference temperature (Tref),
delivered by a sterilization process to an item

z-value:

• The number of degrees of temperature change to


reduce the lethality by a factor of 10
• The z-value allows integration of the lethal effects of
heat as the temperature changes during the heating
and cooling phases of a dry heat process
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 62

62

31
9/18/2019

FH-Value for Sterilization (1)

• A measure of heat input


• The concept is comparable to the F0 concept for
moist heat sterilization
• References lethality to equivalent times at
160°C
– Other reference temperatures can also be considered,
but 160°C is primarily used
• FH values are shown in units of minutes or
seconds
• Calculations of FH use the same equations as
the calculations of F0
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 63

63

FH-Value for Sterilization (2)

• FH- is a term used to model exposure time to


dry heat
• Routine operational processes are not
generally square wave processes
– Therefore the z-value, or temperature coefficient, is
used in the model to calculate the equivalent
lethality at different temperatures such as during
the heat-up and cool down phases

FH: Expressed by a reference temperature so that it truly represents the


equivalent exposure time, in terms of lethality, at that reference temperature

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 64

64

32
9/18/2019

Glossary of Terms:
Routine Operational Process

• Parameters that are specified for ongoing


operations
• Typically controlled to produce additional
lethality over the qualified minimum parameters
(i.e., time and temperature) in order to provide
increased sterility assurance

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 65

65

Glossary of Terms:
Heat-Up Phase

• The phase of a process that


occurs prior to the exposure
phase
• Process parameters are
developed for this phase in
order to meet applicable
user requirements for load
conditioning (e.g., pre-heating)

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 66

66

33
9/18/2019

FH-Value for Depyrogenation

• May be used in dry heat


depyrogenation processes to
calculate the time in minutes
equivalent to a lethality or
endotoxin destruction effect
delivered by dry heat at 250°C
– F-value reference temperature is set
at 250°C

– z-value minimum is set at 46.4°C.

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 67

67

FH Values:
Equation 3.3.1.1-1
Theoretical FH values z-value = 20°C
can be calculated
using the following
parameters: Tref-value = 160°C

The FH values can be determined using the calculation below

n  

T i - T ref 
 
FH  t 10  
 z 
  
 i 
i 1  
 
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 68

68

34
9/18/2019

FH Values (2)
n  

T i - T ref 
 
FH  t 10  
 z 
  
 i 
i 1  
 
FH • Equivalent lethality in minutes
Tref • Reference temperature equal to 160.0 C
z • Spore lethality z-value equal to 20.0 C

Ti • Measured temperature in C during the time


interval “ti”
ti • Time interval of data recording “i” in minutes
n • The number of data recordings
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 69

69

z-Value and D-Value

D-Value z-Value

• The decimal reduction • The number of


time is the amount of degrees of
time (in minutes) temperature change
required at a reference necessary to change
temperature for a one- the D-value by a factor
log, or 90%, reduction of 10
of a microbial • Dry heat sterilization
population under calculations = 20°C
specified lethal
conditions.

Both D-value and z-value are determined experimentally.


Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 70

70

35
9/18/2019

D-Value for Dry Heat Sterilization

Always specify with a reference temperature (DT)

Example

a Biological Indicator (BI) challenge


system with a D160oC= 1.9 minutes,
requires 1.9 minutes at 160oC to
reduce the population by one logarithm

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 71

71

Review Question #7

Dry heat sterilization requires which of the


following:
A. Slow-acting sterilizing agent
B. Higher temperatures
C. Longer exposure times
D. All of the above

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 72

72

36
9/18/2019

Review Question #8

The rate of microbiological destruction


associated with devices and items sterilized
by dry heat is influenced by: (select all that
apply)
A. Temperature
B. Uniformity of the heating medium
C. Carrier
D. Conductivity of the containers
E. Pathway to the heating medium
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 73

73

Review Question #9

The primary factors affecting inactivation of


the microorganism include:
A. Time and temperature
B. Water content, temperature, and time
C. Air and temperature
D. Temperature and number of
microorganisms

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 74

74

37
9/18/2019

Biological Indicators (BI)


• Synonyms Note: Important to
− BI Challenge System evaluate the dry heat
resistance of the BI in
− Microbial Challenge the actual
− Microbiological Challenge System configuration to be
tested for validation as
• Characterized by the following: resistance of the
− Name of the species of bacterium used microorganisms may
− Number of the strain in the original be affected by the
substrate upon which
collection
they are placed
− Number of viable spores per carrier
− D-value
Biological Indicator Challenge System (BI): A standardized preparation of
selected microorganisms used to assess the effectiveness of a sterilization
procedure during process development and validation.
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 75

75

Dry Heat Sterilization: BIs

• Use microbiological challenges specific to


dry heat sterilization processes
• Spore preparations
– Clean
– Well characterized with respect to their thermal
responsiveness
– “Parent” cultures obtained from recognized
culture collections
• Some sources:
– American Type Culture Collection (ATTC)
– National Collection of Industrial, Marine, and
Food Bacteria (NCIMB) Image courtesy of aiu.edu

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 76

76

38
9/18/2019

BI Selection and Type of Carrier (1)

• Available in a variety of configurations


including:
– Spore suspensions in solutions
– On paper carriers (i.e., spore strips or
discs)
– Other types of carriers
• The most common BI microorganism
used is Bacillus atrophaeus
– For qualification of dry heat sterilization
Image courtesy of krackeler.com
processes using the overkill design
approach
– However, other dry heat sterilization
resistant biological indicators could be
acceptable
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 77

77

Biological Indicator Selection


and Type of Carrier (2)
Considerations Resistance of the test strain to the
when selecting particular sterilization method is greater
indicator organisms: than the resistance of microorganisms
potentially contaminating the item or
component
Test strain is non-pathogenic

Test strain is easy to culture

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 78

78

39
9/18/2019

Biological Indicators:
Sterilization Process
• The sterilization process can be
evaluated in one of two ways
– The BI can be exposed to a partial
process and the kill rate is calculated
– The BI can be exposed to an overkill
process
• Perform a determination of the stability of the
population and resistance of the BI
• Base the actual population and resistance on the
desired lethality and the design approach (e.g., overkill or
product specific approach)

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 79

79

BI Vendor/Shipping and Handling


If the reliability of a vendor’s
Certificate of Analysis is
Supplied values for resistance of established through a supplier
a biological indicator can be used qualification program
in lieu of confirmatory testing of
each lot
And the BI is not modified

• Confirmatory spore population testing should be conducted upon


receipt of biological indicators due to potential shipping and
handling concerns
• Shipping and handling procedures should be assessed to ensure
no BI adulteration has occurred (e.g., x-ray)
• It is important to use the same enumeration methodology that the
vendor used in order to minimize variables that could lead to
differences in spore count
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 80

80

40
9/18/2019

BIs and Dry Heat Sterilization

• Compendia (e.g., USP, EP, JP) contain monographs


defining BIs that may be used in evaluating dry heat
sterilization
• It is recommended that consideration is given to
applicable regulatory expectations

Image courtesy of tinhangtech.com

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 81

81

Review Question #10

A BI is characterized by the following:


A. Name of the species of bacterium
B. Number of the strain in the original
collection
C. Number of viable spores per carrier
D. All of the above

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 82

82

41
9/18/2019

Review Question #11

The sterilization process can be evaluated in


one of two ways:
A. Calculate FH-value and survivor curve
B. Expose BI to a partial process and
calculate the kill rate or expose BI to an
overkill process
C. Vortexing and sonication

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 83

83

Section 4.0:

Equipment Design

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 84

84

42
9/18/2019

Equipment Design
• Validation of dry heat depyrogenation and
sterilization cycles is dependent upon
– Equipment
– Load to be processed
• Goal is to deliver effective processes that are
consistent and reproducible
• Design and construction of the equipment governed
by User Requirement Specifications (URS)
• Successful qualification
– Formal verification of proper design
– Installation and operational testing
• Ensures design criteria and specifications are met
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 85

85

Overview

Design

Equipment Qualification

User
FAT SAT Installation Operational Performance
Requirements

Physical (Micro)Biological

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 86

86

43
9/18/2019

Glossary of Terms:
Sterilization Cycle

A sequence of defined
operating parameters
(e.g., time and
temperature) and
conditions required to
render an item sterile.

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 87

87

Equipment Design: (1)


User Requirements Specifications (URS)

• Identify the following:


– Oven and tunnel requirements
– Type of load to be processed
• Provides basis for:
– Specification
– Design
– Verification

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 88

88

44
9/18/2019

Equipment Design: URS (2)

Installation and process requirements


Performance
Temperature requirements Environmental
ranges (e.g., production classifications
capacity)

Installation
location Safety
Control strategy
requirements considerations
and conditions

Utility
requirements

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 89

89

Equipment Design:
Dry Heat Process

Predominant
method
Forced
Accomplished Convection
by transferring Focus of
heat to the tunnel and
load through oven design
several means Conduction

Convection: The transfer of heat by the circulation or movement of the


heated liquid or gas.

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 90

90

45
9/18/2019

Equipment Design:
Convection Heating

Method of transferring heat


through a medium by motion of
its parts
Image courtesy of proprofs.com

• Facilitated by the action of a mechanical


Forced
device (typically a fan), with air passed
Convection
through HEPA or ULPA filters to provide a
Heating
low particulate environment

• A result of the buoyancy forces


Natural
generated by differences in density
convection
caused by temperature gradients in the
Heating
fluid mass
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 91

91

Equipment Design:
Dry Heat Process

Forced
Accomplished
Convection
by transferring
Molecular
heat to the
Interaction
load through
several means Conduction
“Free”
Electrons

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 92

92

46
9/18/2019

Equipment Design:
Conduction Heating

Image courtesy of www.vtaide.com

• Molecules at higher energy levels


Molecular
impart energy to adjacent molecules
Interaction
at lower energy levels

• The ability of solids to conduct heat


depends on the “free” electron
“Free” concentration
Electrons • Pure metallic solids contain the highest
concentration (best conductors of heat)
• Non-metals contain the lowest (poorest
conductors of heat)
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 93

93

URS: HEPA Filters

• Heated air forced through these filters


provides an environment with an appropriate
level of particulates suitable for components
being processed
• Heated air is provided to the clean zone that
heats the glassware to depyrogenation
temperatures for the time required for
endotoxin reduction

Note: A later section will discuss design and test parameters for HEPA
filters used in dry heat ovens and tunnels.
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 94

94

47
9/18/2019

URS:
Oven and Tunnel Considerations

• Non-reactive interior surfaces with smooth


seams and corners
• High temperature, non-shedding gaskets
• Sealed fan bearings
• Sealed control or access penetrations into the
chamber
• Minimize sharp corners and expansion joints

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 95

95

Equipment Design:
HEPA or ULPA Filters (1) Image courtesy of techrite.com

• High continuous temperature


design
– Composite filters – 350°C
– Ceramic filters – 400°C
• Temperature limit dependent on sealant type
and filter construction
• Define leak testing at process temperature
for on-going assurance
• Organic challenge agents discouraged

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 96

96

48
9/18/2019

Equipment Design:
HEPA and ULPA Filters (2)

• Filters should be constructed of materials that


minimize particulate shedding due to temperature
changes
• Items to consider for high temperature HEPA or
ULPA filters include:
– Non-ferrous metal frame
– High temperature glass fiber media
– High temperature sealant
– Non-shedding filter packing
– High temperature gaskets Image courtesy of thermalproductsolutions.com

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 97

97

Equipment Design:
HEPA and ULPA Filters (3)

• After installation follow filter manufacturer’s


instructions for curing (burn-off) the filters
at high temperature
• Binders will outgas (burn-off) from the
media
• Install filters with vertical frames with pleats
in vertical position to prevent media sag

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 98

98

49
9/18/2019

Glossary of Terms

Image courtesy of epsovens.com Batch Oven:


• A convection oven with a chamber or chambers where items
are dry heat sterilized or depyrogenated as a single load in a
discontinuous process
• An oven that uses fans to circulate High Efficiency Particulate
Air (HEPA or Ultra Low Particulate Air (ULPA) filtered heated
air around the articles to be sterilized or depyrogenated
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 99

99

Equipment Design:
Batch Convection Oven
• Typically controlled and monitored
by a programmable temperature
control system
– Provide appropriate temperature ramp,
exposure and cool down
Image courtesy of despatch.com • Monitor air flow and pressure
differential provided by the oven fan
• Control door interlocks during the
process and until the processed
load is unloaded to prevent ingress
into the oven

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 100

100

50
9/18/2019

Equipment Design:
Interlock System on a Double Door Batch
Convection Oven

• Mechanism to prevent:
– Opening of either door out of sequence
– Or both doors at the same time
• Maintain pressure gradient in an
environmentally controlled area:

Unloading Loading
Chamber
Area Area
Highest
pressure

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 101

101

Equipment Design:
Batch Convection Oven

Measure
Filter air differential
intake and pressure
exhaust vents across filters

Conduct risk
assessment to
determine the
type of filter
needed

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 102

102

51
9/18/2019

Example of Batch
Figure 4.1.2-1:
Convection Oven Showing Airflow

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 103

103

Equipment Design:
Continuous Convection Tunnel (1)
• Conveyor system moves load through heated
tunnel
– Predetermined load
– Predetermined rate
• May include three zones: Image courtesy of www.enceko.pl

Load/Preheat • Pre-warm glassware


Zone
• Glassware exposed to process temperature
Hot Zone for sufficient time to effect sterilization and
depyrogenation

• Cool glassware to room temperature prior to


Cool Zone exiting sterilizer
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 104

104

52
9/18/2019

Equipment Design:
Continuous Convection Tunnel (2)

• Correlates to exposure time


Conveyor
• Document
speed is
critical • Variable speed accommodates vial
sizes

• Temperature control of hot zone is


required
Temperature
• Temperature distribution can vary with
load
Image courtesy of bio-world.com
• Temperature high limit controls are
required for continuous processes

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 105

105

Figure 4.1.3-1:
Continuous Convection Tunnel

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 106

106

53
9/18/2019

Equipment Design:
Continuous Convection Tunnel (3)

• Differential pressure ranges across zones


minimize cool zone air entry into discharge
area
• Set and document position of gates between
zones
• Monitor cool zone to assure items are cooled
to appropriate temperature
– Sanitized by a qualified sanitization process
– Frequency of sanitization determined by risk

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 107

107

Equipment Design:
Cool Zone Decontamination Methods

Cool Zone self- Exposure to


decontamination disinfectants/ Manual cleaning
by thermal sterilants and sanitization
means (vaporized hydrogen
peroxide)

• Incorporate controls into tunnel design


• Disinfectants/sterilants could also be drawn from
the room into cool zone

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 108

108

54
9/18/2019

Equipment Design:
Continuous Tunnels
• Typically include data recorders to monitor the
process and print process reports
• Monitor physical parameters
– Conveyor speed
– Temperature of the pre-heat zone
– Heat zone and cool down zones
– Forced air fan alarms
– Zone pressure
• System alarm indicates deviation from process
specifications
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 109

109

Review Question #12

Which of the following are considered in the


specification, design, and verification of the
equipment: (select all that apply)
A. Type of load to be processed
B. Temperature requirements
C. Selection of HEPA filters
D. Environmental classifications

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 110

110

55
9/18/2019

Review Question #13

The predominant method of the dry heat


process includes which of the following:
(select all that apply)
A. “Free” electrons
B. Forced convection heating
C. Molecular interaction
D. Natural convection heating

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 111

111

Review Question #14

What factor affects the temperature


distribution in a continuous convection
tunnel?
A. Conveyor speed
B. Full, empty, or partially loaded tunnel
C. Different size containers

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 112

112

56
9/18/2019

Section 5.0:

Equipment Qualification

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 113

113

Equipment Qualification:
Process Equipment

 Check process equipment and associated


systems for proper operation
• Factory acceptance testing
• Commissioning
• Installation qualification
 Verify materials of construction
• URS
• Manufacturer’s specification

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 114

114

57
9/18/2019

Glossary of Terms

Commissioning:
• A well planned, documented and managed engineering
approach to the start-up and transfer of facilities, systems and
equipment to the end-user that results in a safe and functional
environment that meets established design and user
requirement specifications.
• Commissioning precedes Qualification and includes three
phases:

2) Adjustment
1) Inspection and 3) Functional/
and Setting to
Testing, Regulation Run Testing
Work

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 115

115

Equipment Qualification (1)


Qualification of equipment
controls typically includes:
• Verification of alarms
• Set points
• Temperature control
• Interlocks
• Sequence of operations

Operational Qualification

• Functional testing of all process steps


• Ensures correct sequence of operation
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 116

116

58
9/18/2019

Glossary of Terms: Verification

• A systematic approach to verify that


manufacturing systems, acting singly or in
combination, are fit for intended use, have
been properly installed, and are operating
correctly
• An umbrella term that encompasses all types
of approaches to assuring equipment is fit for
use such as qualification, commissioning and
qualification, verification, system validation, or
other
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 117

117

Equipment Qualification:
Additional Functionality Testing (2)

• Focus on critical process parameter alarms


• Ensures equipment can reliably indicate
non-conforming and unsafe operating
conditions
• Completed as a separate test during OQ or
included in the testing of overall operation of
the unit
Critical Alarm Testing: A series of tests to determine if the electro/mechanical
operations described in the equipment specification perform as stated

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 118

118

59
9/18/2019

Table 5.0 –1: Example of Equipment


Qualification Checklist (1)
Checklist Item Batch Continuous
(Oven) (Tunnel)
Electrical Program Logic – ensure that each step is in X X
the correct sequence and that it is repeatable
Verification of alarms – ensure alarms operate as X X
specified (e.g., system overloads, interlocks)
Item Interlocks Overload – must work correctly, not X
allowing excess item buildup during processing
Door Interlocks – must work correctly, not allowing X
access during the process
Gasket Integrity – X X
Ovens: check for positive/negative pressure seal of all
door gaskets
Tunnels: check that the leakage rate does not exceed a
predetermined value at all panel gaskets from zone to
zone and to the external environment

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 119

119

Table 5.0 –1: Example of Equipment


Qualification Checklist (2)
Checklist Item Batch Continuous
(Oven) (Tunnel)
Air Balance – check that the ∆P meets defined requirements X X
respect to the preparation section through the tunnel.

Vibration Analysis – check blowers for correct dynamic X X


balancing to minimize vibration
Louver Balance Ability – check that louver/linkage X
mechanisms can be actuated and adjusted for balance
Louver Position- document position of manually adjusted X X
Louvers (as applicable)
Gate Balance Ability – check that gate control mechanisms X
can be actuated and adjusted for balance
Blower Rotation – check that blowers rotate in the specified X X
direction

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 120

120

60
9/18/2019

Table 5.0 –1: Example of Equipment


Qualification Checklist (3)
Checklist Item Batch Continuous
(Oven) (Tunnel)
Blower Revolutions Per Minute (RPM) – verify that X X
the correct blower RPM is achieved
Heater Elements - check that all heater elements X X
operate
Room Balance – check that the ∆P balance is positive X X
from the sterile core to the preparation area when the
tunnel or double door batch oven is in operation
Verify HEPA Filter Integrity X X
Temperature Sensor – ensure temperature sensors are X X
installed appropriately (location, orientation).
Belt Speed – verification of correct belt, speed X
controller and recorder

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 121

121

Equipment Qualification:
Final Check
• A series of processes to verify each system
component
– Interacts correctly
– In the programmed sequence of events is
repeatable
• Use the appropriate standards for calibration
tolerance and calibration frequency for
instruments used to:
– Monitor critical operational parameters
– Monitor critical quality attributes
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 122

122

61
9/18/2019

Environmental Qualification (1)


• Control of particulates with HEPA or (ULPA) filters
• Pressurization of clean zones and chambers
• Verify particulate levels, clean zone
pressurization and air flow and balance meet
design specifications
• Particulate quality appropriate for exiting
environment classification
• Establish airflow parameters to maintain
temperature uniformity and air quality under
dynamic conditions
• Use airflow velocity readings to determine airflow
uniformity across HEPA filters

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 123

123

Environmental Qualification (2)

• Operational testing verifies aseptic


environment is maintained
• Perform particulate testing at operating
temperature as well as during heat-up
and cool down phases
• Draw samples from worst case locations
• Meet applicable standards for particulate
concentration at a given location

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 124

124

62
9/18/2019

Equipment Verification:
Room Differential Pressure
• Establish requirements for oven or tunnel
• Impacts unit air flow and temperature distribution
• Verify air pressure differentials in operational testing of
sterilizer
• Minimum pressure differential established is dependent
on the system design
• Verify air balance between sterilizer and outside
environment

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 125

125

Review Question #15

Qualification of equipment controls typically


includes:
A. Verification of alarms, set points,
temperature control, interlocks, and
sequence of operations
B. Functionality testing of all process
steps
C. Factory acceptance testing,
commissioning, and Installation

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 126

126

63
9/18/2019

Review Question #16

It is important to verify that each system


component interacts correctly and
repeatability in the programmed sequence
of events.
A. True
B. False

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 127

127

Uniformity of Heat

• Perform temperature distribution studies


to establish appropriate air flow which
ensures thermocouple accuracy:
– Batch Ovens
– Tunnels

Image courtesy of www.enginebuildermag.com

Temperature Distribution: Temperature measurement of the heating


medium (e.g., forced hot air) across the chamber load zone
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 128

128

64
9/18/2019

Uniformity of Heating Media:


Batch Ovens

• Adjust discharge louvers


• Document position
• Obtain uniform temperature
profile
• Monitor the particulate quality of discharge air
at process temperature
• Ensure that it falls within pre-established
acceptable limits

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 129

129

Uniformity of Heating Media:


Continuous Tunnels

• Adjust air supply


– Controlled flow
– Change fan speed or damper position
• Ensure air quality at process temperature
• Data used as basis for future flow
pattern modifications
• Determine number and type of tests
necessary

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 130

130

65
9/18/2019

Empty Chamber Temperature


Distribution (Ovens and Tunnels)
• Confirms air balance and heated air
supply provides even heating
• Typically multiple runs to confirm
reproducibility of:
Heating
Cool
Heat up time medium
locations
uniformity

• Establish process temperature set point


– Minimum temperature specification

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 131

131

Empty Chamber Temperature


Distribution: Batch Oven

• Distribute thermocouples throughout the


chamber load zone
• Represent horizontal, vertical, and lateral planes
• Thermocouples should not contact internal
surfaces
• Place thermocouple close to control
thermocouple and correlate average temperature

Load Zone: Area within in the chamber where materials to be sterilized or


depyrogenated may be placed.

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 132

132

66
9/18/2019

Empty Chamber Temperature


Distribution: Continuous Tunnel

• Distribute thermocouples across belt width


– Affix to belt or mounting bar
– Measure at entrance, exit, load zone
• Thermocouples should not contact internal
surfaces
• Placement height representative of
anticipated load
• Place thermocouple close to control
thermocouple (where possible) and correlate
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 133

133

Temperature Distribution Qualification

• Confirm critical and key operating


parameters
• Document
• Tunnels at nominal set points
– Belt speed
– Hot zone temperature
• Define equilibration time
• Evaluate temperature variability
Image courtesy of www.comsol.com

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 134

134

67
9/18/2019

Review Question #17

Temperature distribution studies are performed


to establish:
A. Proper calibration tolerance and
calibration frequency
B. Appropriate air flow to ensure equipment
performance
C. Room differential pressure requirements
for the oven or tunnel

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 135

135

Review Question #18

Multiple empty chamber distribution tests are


performed to confirm: (select all that apply)
A. The air balance and heated air supply
will provide even heating
B. Reproducibility of heat-up and cool
locations
C. Heating medium uniformity

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 136

136

68
9/18/2019

Section 6:

Process
Development

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 137

137

Process Development

Goal: Identify critical and key operating


parameters

Select items constituting load

Determine thermal dynamics of


chamber

Determine thermal profile of the


items and loading patterns
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 138

138

69
9/18/2019

Process Development

• Represent actual
manufacturing
conditions (e.g.,
spraying vials with water
to simulate vial washing)
• Document
Image courtesy of www.pharmaceutical-int.com development process

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 139

139

Process Development:
Process Design Approaches

Overkill Design Product Specific


Approach Approach

Both approaches provide a process that delivers


the appropriate level of sterility assurance or
endotoxin reduction to the items being
depyrogenated or sterilized

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 140

140

70
9/18/2019

Process Development:
Overkill Design Approach

• Depyrogenation Process
– Demonstrate a minimum of a 3 log reduction of endotoxin
at the coolest location in the worst load
• Sterilization Process
• Biological indicators used to demonstrate lethality
− Known population
− Resistance
• Bacillus atrophaeus generally used
• Deliver a probability of a non-sterile unit (PNSU) that is
less than or equal to 10-6
Note: Consider the potential for thermal degradation of items when overkill used
Probability of a Non-Sterile Unit (PNSU): The number that expresses the
probability of occurrence of a non-sterile unit after exposure to a sterilization
process
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 141

141

PNSU Formula

The probability of a non-sterile unit at the minimum FH delivered in


the load can be calculated using the following equation:

Log PSNU = -FH/D + Log No

FH = Lowest FH No = initial
D = D160C-value of the BI
calculated within load population of BI
D160C-value = 2 minutes
FH = 30 minutes N0 = 1 x 106

Log PSNU = -30 minutes/2minutes + 1 x 106


Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 142

142

71
9/18/2019

Calculation of PNSU

Log PSNU = -30 minutes/2minutes + 1 x 106

Log PSNU = -30/2 + 6


Log PSNU = -15 +6
Log PSNU = -7
PSNU = 10-7
Therefore, the predicted probability of a non-sterile
unit at the coolest area within the load (lowest FH
value) is 10-7 (not more than 1 non-sterile unit in 107
units) which is well in excess of the accepted
standard of 10-6.
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 143

143

Process Development:
Product-Specific Approach (1)

• Used to develop sterilization


cycles for heat labile items
• Determine population and heat
resistance of microorganisms
in/on product
• Design process to result in a
PNSU of 10–6

Product-Specific Design Approach: A sterilization design approach that is


based on the characteristics of the bioburden (on or in the load) and the heat
sensitivity of the product that delivers the lethality needed to achieve a PNSU ≤ 10-
6 on or in the items to be sterilized.

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 144

144

72
9/18/2019

Process Development:
Product-Specific Approach (2)

• Inactivation of microbial challenge to a


predetermined level demonstrates that the
desired probability of survival of product
bioburden is achieved
• Bioburden must be monitored
• Frequency of monitoring determined through
risk assessment

Note: For additional detail on the product specific design approach


to sterilization, see PDA Technical Report No. 1.
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 145

145

Process Development:
Defining Operating Parameters

• Critical operating parameters


– Temperature
– Exposure time (conveyor speed)
• Additional key parameters
– Time and temperature during heat up and
cool down phases
– Pressure differentials

Operating Parameters: Values (e.g., time, temperature, air-flow) that are


controlled and/or measured that collectively define each phase of a process
(e.g., heat-up, exposure, cool-down).
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 146

146

73
9/18/2019

Critical Process Parameters


and Key Parameters
Critical Process
Key Parameters
Parameters (CPP)
• Values that are • Values that are
controlled and/or controlled and/or
measured measured
• Linked to safety and • Used to assure the on-
efficacy of a product or going “state of control”
the process and consistency of
• Reject load if failure to runs
meet a critical • Investigate failure to
parameter meet a key process
parameter

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 147

147

Process Development:
Operational Parameters (1)
 Develop operational parameters that ensure
 Sterilization: minimum PNSU of a least 10-6
 Depyrogenation: minimum 3 log reduction in endotoxin
 Achieve parameters within the loads or
components
 Use as a starting point for process or process
development
 Perform temperature studies to determine worst
case conditions in load

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 148

148

74
9/18/2019

Review Question #19

The goal of process development is to identify


critical and key operating parameters that will
result in a load meeting the minimum
acceptance criteria for depyrogenation/
sterilization
A. True
B. False

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 149

149

Review Question #20

The two process design approaches include:


A. Sterilization and Depyrogenation
B. Overkill and Product-Specific
C. Sterility Assurance and Endotoxin
Reduction

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 150

150

75
9/18/2019

Review Question #21

Operational parameters for depyrogentation


should: (select all that apply)
A. Achieve a minimum PNSU of at least 10-6
B. Achieve a minimum 3 log reduction in
endotoxin
C. Be achieved within the loads or
components being processed

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 151

151

Process Development:
Batch Oven Process Development

• Identification of loading patterns and worst case


load
• Temperature distribution studies verify heating
uniformity of the load zone
• Heat penetration studies demonstrate
temperature being delivered to items in load for
the appropriate time
• Typically determined using temperature
measurements
• Confirmed with BI or EI challenge testing

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 152

152

76
9/18/2019

Batch Oven:
Developing Load Patterns (1)
• Determine ‘worst case’ load based on
– Load mass
– Configuration
– Other parameters
• Verify choice
• Develop process parameters to achieve required
conditions of time and temperature
• Ovens: industry experience demonstrates validation of
maximum load for a given load configuration is considered
sufficient to validate loads of less mass (i.e. minimum
loads)

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 153

153

Glossary of Terms:
Worst Case, Maximum, and Minimum Loads

Worst Case Load: The load configuration that is


determined to be most difficult to sterilize or depyrogenate.
This is a function of the process control strategy and load
item characteristics (e.g., mass, configuration)

Minimum Load: The minimum quantity or mass of items


permitted in a depyrogenation or sterilization load

Maximum Load: The maximum quantity or mass of items


permitted in a depyrogenation or sterilization load

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 154

154

77
9/18/2019

Batch Oven:
Developing Load Patterns (2)

• Allow adequate space in load configuration


– Air circulation
– Penetration by heat
– Removal of moisture
• Consider wrapping or container type
− Protects against contamination (microbial and
particulate)
− Ensures adequate air movement and moisture
removal

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 155

155

Batch Oven:
Developing Load Patterns (3)
• Raise large items (not on cart) off of floor to
allow air circulation
• Trolley position within the oven must be
reproducible and included in load pattern
documentation
• Load orientation can affect item heat up
• Trays, racks, carts
• Should not generate particulates
• Must withstand heating process without
degradation
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 156

156

78
9/18/2019

Batch Oven:
Developing Load Patterns (4)

Identification of worst case


Heat penetration studies
location or hardest to
using FH values may be
sterilize/depyrogenate
useful to identify hardest to
locations in the load should
sterilize/depyrogenate
be performed by analysis of
areas.
heat penetration studies.

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 157

157

Loaded Batch Oven


Temperature Distribution Studies (1)

• Primary purpose is to verify temperature


distribution of the heating medium across the
load
• May be conducted concurrently with heat
Image courtesy of www.despatch.com
penetration studies
• Place temperature thermocouples in load
– Not in contact with the items or oven hardware
(e.g., carts, shelves, trays)
• Document sensor locations for each load Image courtesy of picotech.com

Thermocouple: A device for measuring temperature in which a pair of wires of


dissimilar metals (such as copper and iron) are joined and the free ends of the
wires are connected to an instrument (such as a voltmeter) that measures the
difference in potential created at the junction of the two metals.
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 158

158

79
9/18/2019

Loaded Batch Oven


Temperature Distribution Studies (2)

• During temperature distribution qualification


confirm and document operating parameters
• Exposure phase acceptance criteria may
include the maximum
– Variation in the temperature measured by
each probe
– Variation in the temperature measured from
probe to probe
– Difference in temperature between the
probes and the control temperature set point

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 159

159

Glossary of Terms:
Exposure Phase/Dwell Time

Exposure Phase: The phase of the process in which the


appropriate parameters are maintained within defined
ranges for the time (exposure time or dwell period) and
temperature determined to be necessary to achieve the
desired lethality

Dwell Time: The period that items are subjected to a


given processing condition. Synonym:

• Synonym: Residence Time


Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 160

160

80
9/18/2019

Loaded Batch Oven


Heat Penetration Studies (1)

Prior to heat penetration studies


• Load characterization through item-
mapping studies may be necessary
• Identifies appropriate monitoring locations
within individual load items

Item-temperature mapping: Determines the location within the item or


package most difficult to heat

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 161

161

Loaded Batch Oven


Heat Penetration Studies (2)
• Data may be used to calculate F-values for each
probe location
• Position temperature probes in the load to determine
the slowest-to-heat location(s) within the load
– Represents most difficult to depyrogenate/ sterilize
– Generally conducted under worst case operating
conditions
• Minimum time and temperature set point

Heat Penetration: Heat penetration testing is a temperature measurement that


is used to evaluate the amount of energy that has been transferred to the
materials within the load. For measurements of heat penetration, the probes
should be placed in the load with the tips of the sensors in contact with the items
being evaluated.
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 162

162

81
9/18/2019

Loaded Batch Oven


Heat Penetration Studies (3)
• For loads with items that have
different heat penetration
characteristics, place probes in
representatives of each item type
• Document Image courtesy of directindustry.com

• Temperature sensor locations for each


qualification load
• Rationale for selecting locations

Penetration Probe: A thermocouple placed in contact with the load item to


measure the temperature of the load item.

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 163

163

Figure 6.3.3-1 Load Profile:


Batch Oven

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 164

164

82
9/18/2019

Loaded Batch Oven


Heat Penetration Studies (4)

• Evaluate effectiveness of process in the


heat penetration study
– Analyze calculated FH values for all temperature
probes
• Use data to determine cold spots which
provides worst case location in PQ
• BI or EI challenge studies can be
conducted concurrently
• Calculate lethality and/or endotoxin
reduction
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 165

165

Continuous Convection
Tunnel Process Development (1)

• Typically used to sterilize and depyrogenate


containers before filling with final product
• The following constitutes an integrated
continuous flow operation

Container Depyrogenation Filling


washer tunnel machines

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 166

166

83
9/18/2019

Continuous Convection
Tunnel Process Development (2)
• Tunnels may operate at a fixed belt speed and the number of
containers varied according to the demand from the filling
machine
• A variable speed belt offers greater operating flexibility and is
more common in newer installations
• The period during which the containers remain within the hot
zone, also referred to as the “sterilization / depyrogenation
dwell time”, is set by conveyor belt speed
• Required dwell time in the tunnel hot zone can be empirically
derived by thermal analysis during empty and loaded chamber
studies
Dwell Time: The period that items are subjected to a given processing condition.
[Synonym: Residence Time]
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 167

167

Continuous Tunnels:
Developing Loading Patterns (1)
• The ‘worst case’ load determined on the basis of the
following
– Load mass
– Configuration
– Other parameters

• Develop process parameters to achieve the required


conditions of time and temperature for the load
• Place load items into the tunnel so they remain upright
• To maintain this load
– The belt speed must be consistent with the washer speed, or
– The belt speed is constant and the width of the load is varied
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 168

168

84
9/18/2019

Continuous Tunnels:
Developing Loading Patterns (2)

• Exposure time controlled by:


– Belt speed
– Set-point temperature
• Temperature of glass is affected by:
– Exposure temperature
– Airflow
– Mass of glassware
• Exposure temperature maintained by a feedback
control loop
– Controls temperature at a constant steady rate
– May vary as the load conditions change

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 169

169

Continuous Tunnels:
Developing Loading Patterns (3)

Example

• When glass first enters the tunnel, the


introduction of cold containers may cause the
tunnel temperature to drop.
• The severity of the drop is dependent on the
response characteristics of the control system.
• Airflow should be regulated and relatively
constant so not to impact temperature.

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 170

170

85
9/18/2019

Continuous Tunnels:
Developing Loading Patterns (4)
• Establish relationship between
Drying/ heating/
Washing Speed cooling zone belt Filling speed
speed

• Load the conveyor belt in a uniform manner to provide


reproducible thermal conditions within the heating zones
• Irregular gaps in the components will produce non-
standard but typically more effective thermal conditions
• These situations may occur in production operation and
are of no consequence
− However they should be avoided during qualification studies
• The process must provide components from the cooling
zone into the aseptic area at a suitable temperature for
filling Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 171

171

Continuous Tunnels:
Developing Loading Patterns (5)
• Introduce loads into the heating zone in a manner
representative of actual manufacturing conditions
• Determine thermometric conditions when the load
enters and exits the hot zone
• The largest load mass/unit area may be validated
as representative of the range of items to be
qualified
• Selection of the worst-case challenge(s)
conducted using scientific rationale and/or
determined through heat penetration or challenge
studies
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 172

172

86
9/18/2019

Continuous Tunnels:
Developing Loading Patterns (6)
Dry Heat The ‘worst case’ load for each temperature
setting must be determined by calculating the
Tunnels throughput of items (expressed in mass/time)

Consider belt speed/item passage time

Consider number and weight of items being


processed in a unit of time (tunnel capacity)

Set belt speed to ensure that dwell time within


hot zone provides required biological
inactivation or endotoxin reduction

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 173

173

Continuous Tunnels:
Developing Loading Patterns Summary (1)
Selection of a “worst case” load simplifies the
validation approach to tunnel depyrogenation by
running studies under conditions which produce a
“worst case” challenge seen in production for the
following three categories:

Mass Rate of
Belt
per unit mass
speed
area loading

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 174

174

87
9/18/2019

Continuous Tunnels:
Developing Loading Patterns Summary (2)
The steps can be summarized as follows:

Load the tunnel


at the maximum
Set the belt rate
speed to the
Select the maximum for
container that any container
produces the
maximum mass
per unit area

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 175

175

Loaded Tunnel
Temperature Distribution Studies
• Assess the impact of
the load on the ability
of the hot zone to
maintain temperature
uniformity
• May be conducted
concurrently with heat
penetration studies
Image courtesy of www.bausch-stroebel.com

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 176

176

88
9/18/2019

Loaded Tunnel Temperature


Distribution Measurement
Measuring Attach sensors to the load near the probed
loaded containers to allow free flow of air around sensor
temperature
distribution Sensing element should not touch the containers

Measures temperature uniformity across width and


length of load

When placing temperature sensors account for cool


areas found during the empty belt chamber studies

Document location of temperature sensor

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 177

177

Loaded Tunnel Temperature


Distribution Performance
• Confirm and document operating parameters
during qualification runs
– Minimum and maximum temperature measured at
each probe position
– Variation in the temperature between probes
– Difference between the probes and set point
temperature
• Operate tunnel at nominal set points for belt
speed and hot zone set point temperature
• Define steady state or equilibration time
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 178

178

89
9/18/2019

Loaded Tunnel Heat


Penetration Studies

• Verifies the worst case load under worst case


operating conditions reaches and maintains
depyrogenation temperatures
• Endotoxin studies can be conducted
concurrently
• Separate EI glassware and glassware for
temperature sensors
– Ex.: Do not use inoculated glassware for the
temperature sensors
• Perform studies in triplicate
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 179

179

Loaded Tunnel Heat Penetration


Studies: Glass Loads
• Replicate residual water left by the normal
washing process when preparing glass loads
– Add representative amounts of water in the items
containing sensors
• Ensure the load is
received into the hot
zone as dry as
possible during line set
up
Image courtesy of penntech-corp.com

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 180

180

90
9/18/2019

Loaded Tunnel Heat


Penetration Studies: Probes
• Use sufficient number of probes
to provide adequate profile of
temperature penetration of the
load
• Place probes in contact with
interior of individual items
• Account for any cool areas found
in temperature distribution studies
when placing probes
• Provide diagrams with specific
temperature sensor locations
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 181

181

Figure 6.4.3-1
Glass Vial Load Heat Penetration Profile:
Continuous Convection Oven

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 182

182

91
9/18/2019

Typical Qualification
Acceptance Criteria

Minimum and
maximum
FH-values
temperatures
achieved

Minimum dwell
Variation in the
time achieved
temperature
above a defined
between probes
temperature
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 183

183

FH-Values

Calculation of an F-value at each


probe location helps:
• Assess process comparability
• Evaluate process repeatability
• Locate cool areas

Note: There is no minimum FH-value acceptance criterion for


depyrogenation. Endotoxin inactivation efficacies cannot be
accurately correlated with standard dry heat lethality conventions
(FH) which rely upon a linear destruction model.

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 184

184

92
9/18/2019

Review Question #22

Batch oven process development consists of:


(select all that apply)
A. Utilities Analysis
B. Identification of loading patterns and worst
case load
C. Temperature distribution studies
D. An integrated continuous flow
E. Heat penetration studies

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 185

185

Review Question #23

During a loaded batch oven heat penetration


study temperature probes should be
positioned in the load to determine the
fastest-to-heat locations
A. True
B. False

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 186

186

93
9/18/2019

Review Question #24

In order to maintain a “tight” load in a


continuous tunnel, so that items that may be
distributed will be held upright by the
neighboring items the following must exist:
A. Belt speed must be consistent with the
washer speed
B. Belt speed must remain constant and the
width of the load must be varied
C. All of the above
D. A or B
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 187

187

Review Question #25

Selection of the worst case load for tunnel


depyrogenation
A. Simplifies the validation approach
B. Is conducted through heat penetration
studies
C. All of the above
D. None of the above

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 188

188

94
9/18/2019

Section 7:

Performance
Qualification
Performance Qualification (PQ): Documented verification that a system
is capable of consistently performing or controlling the activities of the
processes it is required to perform or control, according to written and
pre-approved specifications, while operating in its specified operating
environment

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 189

189

Performance Qualification

• Performance Qualification
– Process of obtaining and documenting evidence that the
equipment, as installed, consistently operates in
accordance with predetermined criteria

Components of Performance Qualification

Biological
Physical Qualification
Qualification

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 190

190

95
9/18/2019

Performance Qualification:
Physical Qualification (1)
• Ensures the depyrogenation/ sterilization
process as developed is reproducible
– Physical Qualification
– Endotoxin/endotoxin qualification
• Verifies temperature profiles within the oven or
tunnel
• Ensure items reach required temperature for
specified time
Physical Qualification: A component of performance qualification that
demonstrates that pre-determined physical requirements including
temperature distribution and heat penetration are achieved consistently
throughout the load.
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 191

191

Performance Qualification:
Physical Qualifications (2)
• Confirm reproducibility of temperature
profiles developed in process development
by performing temperature distribution and
heat penetration qualification with ‘worst’
case loads
• Place calibrated temperature probes in the
coolest locations established during
process development temperature
distribution and heat penetration studies
• Confirm during heat penetration
qualification that items exiting the tunnel to
the filling suite are cooled to a product-safe
temperature Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 192

192

96
9/18/2019

Performance Qualification:
Biological Qualification
• Demonstrates that the required endotoxin
inactivation or lethality is achieved
consistently throughout load
– Endotoxin
– Biological Indicators
• Place indicators in numerous locations in
the load, including the most difficult to
depyrogenate or sterilize locations
Biological Qualification: A component of performance qualification that
demonstrates, by use of biological indicators, that the required lethality is
achieved consistently throughout the load.
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 193

193

Biological Qualification:
Dry Heat Depyrogenation
Validation data demonstrates the process consistently
reduces endotoxin by three (3) logs
• Inoculate articles to be treated with a minimum of 1,000
International Units (IU) of endotoxin per article
• Inoculated articles tested for endotoxin to demonstrate at
least 3 log reduction from original concentration after
treatment in the dry heat depyrogenation process
− Limulus Amebocyte Lysate (LAL) test
− Bacterial Endotoxins Test (BET)
• Where depyrogenation has been demonstrated,
sterilization is assured due to the lower resistance of
microorganisms to dry heat (as compared to bacterial endotoxin).
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 194

194

97
9/18/2019

Biological Qualification:
Dry Heat Sterilization
Validation data demonstrates the process
consistently delivers a microbial survivor
probability for the challenge organism of not less
than 10-6
• Select number of BIs and processes for
performance qualification (PQ) to cover
range of conditions in load during routine
processing
• Placement of BIs based on data from
process development
• Place each heat penetration probe in the
load adjacent to a BI location

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 195

195

Performance Qualification:
Biological Indicator Testing (1)

• Follow manufacturer’s
directions for use
– Medium and conditions to
be used for the recovery of
microorganisms after
exposure to the sterilization
process
• Aseptic technique when
testing BIs
• Investigate positive BIs
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 196

196

98
9/18/2019

Performance Qualification:
Biological Indicator Testing (2)
If a Determine the spore population, confirm purity
suspension and identity of the BI
is used for
direct or Stock suspension should be predominantly
carrier spores in a non-nutritive liquid
inoculation,
consider the Determine the D-value (This is done on the
following item being sterilized if the BI is inoculated onto
the item)
points:
Preparation of the BI needs to be carefully
controlled for purity, protecting the D-value,
protecting the count, and so forth
Determine worst case inoculation site on the
item to be inoculated based on slowest to heat
location.
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 197

197

Performance Qualification:
Endotoxin Indicator Testing (1)
• Widely accepted method that demonstrates overkill or a
three log reduction of endotoxin
– Inoculation of endotoxin onto materials to be depyrogenated
– Recovery of endotoxin spike from treated components

• The stages of such testing via dry


heat depyrogenation process are:
– Preparation and inoculation/
endotoxin spike application and
controls
– Dry heat treatment process
– Recovery
Image courtesy of brass-asiapacific.com
– Endotoxin log reduction calculation
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 198

198

99
9/18/2019

Performance Qualification:
Endotoxin Indicator Testing (2)
• Use actual items or representative coupon of
surface type to be depyrogenated
– Heat resistance and effectiveness of the
depyrogenation process may be influenced by
carrier type
• Adsorption of endotoxin spike to carrier surface is
biggest obstacle affecting recovery
• Use commercially available EIs or endotoxin
challenge vials in place of actual production items
or representative coupons
– Must demonstrate equivalent or worst-case
challenge to the depyrogenation process
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 199

199

Performance Qualification:
Endotoxin Indicator Testing (3)

Conduct preliminary studies with the selected


endotoxin indicator, the inoculation, drying
and recovery methodology prior to
performing depyrogenation validation studies

Image courtesy of gen-biotech.com

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 200

200

100
9/18/2019

Performance Qualification:
Process Equivalency (1)

• Possible to establish the equivalence of:

– Two or more dry heat batch processes (chambers)


OR
– Continuous processes (tunnels) similar in design
(including utilities being supplied)

• Recommend a robust risk analysis process to


make this determination

• Analysis includes, but is not limited to, a design


and engineering evaluation

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 201

201

Performance Qualification:
Process Equivalency (2)

Some Chamber or tunnel size and configuration


factors to
consider Airflow dynamics
include:
Temperature come-up and uniformity

Conveyor speed

Temperature equilibration time

Materials of construction

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 202

202

101
9/18/2019

Performance Qualification:
Process Equivalency (3)
• Regulatory approval may
be required to support a
reduction in qualification
testing

• In order to demonstrate equivalency all


processes must be qualified and meet
operating parameter acceptance criteria

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 203

203

Performance Qualification:
Operational Equivalence
• Established by an analysis of all process data
associated with validated process in new
equipment
• Compare chamber and load profiles using the same
critical process parameters
• Confirm the specifications, acceptance criteria, and
load configuration are the same as those used in
established sterilization validation process of
existing equipment

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 204

204

102
9/18/2019

Performance Qualification

Comparable criteria include the following


parameters such as:

Heat
Load Temperature
penetration, FH
configurations distribution
value range

Heat-up and
BI or EI cool down times
inactivation of the
product/item

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 205

205

Review Question #26

Dry heat depyrogenation validation data


should demonstrate that the process
consistently delivers a microbial survivor
probability for the challenge organism of not
less than 10-6
A. True
B. False

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 206

206

103
9/18/2019

Review Question #27

What is the biggest obstacle affecting recovery


for a Endotoxin Indicator Test?
A. Adsorption of the endotoxin spike to the
carrier surface
B. Heat resistance and effectiveness of the
depyrogenation process
C. All of the above
D. None of the above

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 207

207

Review Question #28

In order to establish process equivalency the


following is recommended to make this
determination:
A. An analysis of all the process data associated
with a validated process in the new equipment
B. A robust risk analysis process including a design
and engineering evaluation
C. A comparison of chamber and load profiles using
the same critical process parameters

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 208

208

104
9/18/2019

Section 8:

Ongoing Process
Control

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 209

209

Ongoing Process Control

Conduct ongoing control and monitoring of


the process

After
After release of
On a continual completion of
the equipment
basis performance
for use
qualification

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 210

210

105
9/18/2019

Ongoing Process Control:


Important Elements
• Review of critical operating parameters for routine
release
• Evaluation of changes
• Periodic revalidation of equipment
• An effective preventative maintenance program to
include filter integrity testing
• Instrument calibration
• Inspection of component wear (i.e., belts)
• Periodic revalidation of the process as necessary
to confirm effectiveness

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 211

211

Ongoing Process Control:


Routine Release
• Develop, perform and document
procedures for on-going monitoring of
routine operational processes
• Document, review, and maintain
critical and key parameters for each
process
• Reject processes that have not met
minimum defined critical parameters Image courtesy of gbengaadebayo.com

• Investigate key parameters not met


and determine load disposition
following investigation results

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 212

212

106
9/18/2019

Ongoing Process Control:


Operational Parameters

Oven: Tunnel:
• Time at temperature • Temperature
(such as minimum heat up
time, minimum exposure or • Conveyor belt
dwell time and minimum cool- speed
down)
• Temperature set- • Differential
point exposure pressure
(between tunnel and clean
• Differential pressure room/cold zone/ tunnel room)
as applicable (e.g.,
between double door batch
oven and a room)

Note: Compendial sterility or biological indicator testing may be required to


support product release.
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 213

213

Ongoing Process Control:


Preventive Maintenance

• Establish program to
assure that ovens and
tunnels remain
mechanically sound and
capable of continuously
meeting process
requirements
• Consider vendor
recommendations

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 214

214

107
9/18/2019

Ongoing Process Control:


Points to Consider for PM Program (1)
 Check the oven/tunnel blowers for excessive
vibration
 Visually inspect and test all critical filters
 Lubricate motors
 Visually inspect the conveyer and belts for
unusual wear (tunnel)
 Inspect for unusual wear
– Motors of the conveyor
– Recirculation fan
– Fresh air fan
– Exhaust air

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 215

215

Ongoing Process Control:


Points to Consider for PM Program (2)
 Inspect the cooling water system control valves
 Inspect pneumatic lines for leaks, cracking or
moisture
 Define replacement frequency of HEPA or
ULPA filters
 Inspect door seals
 Inspect tubing of the differential pressure
transducers
 Check and inspect the tunnel and oven
screens for debris and broken glass
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 216

216

108
9/18/2019

Ongoing Process Control:


Change Control / Revalidation (1)
A change control program maintains the state of
control
• Document equipment, process, and product changes
• Include documentation of any testing required to
ensure the validated state of control
• Evaluate equipment or process changes
– Determines potential effects of those changes
– Demonstrates modified equipment or process performs as
intended and meets established acceptance criteria

Revalidation: Repeating partial or full validation of a process after a


process change is implemented. Change-based, not time based

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 217

217

Ongoing Process Control:


Change Control / Revalidation (2)

Change control program continued


• Review changes made to product/item to identify
potential impact the change has on existing
validation
• Consider
− Worst case product/item selected for
use in validation testing
− Impact to the thermal conductivity of the
product/item
• Determine assessment of
equipment, process, and Image courtesy of www.ipmglobal.net

product/item changes for revalidation


Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 218

218

109
9/18/2019

Ongoing Process Control:


Change Control Requests
• Identifies documents that may be affected by the
change and includes:
– Description of the proposed change
– Documented reason/rationale for proposed change
– A description of the tests needed to revalidate the process
– Technical rationale supporting no impact on process
efficacy (minor change)
– Supporting documentation for tests performed,
interpretation of results and conclusions
– Confirmation that documents affected have been updated
– Approval of the change control package by the Quality Unit
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 219

219

Ongoing Process Control:


Periodic Requalification of Equipment (1)

• Re-qualify equipment on a routine schedule to


ensure there has not been an undetected
change
• Perform and document requalification using
qualified operational parameters and
acceptance criteria
• Results should demonstrate that the
equipment’s performance has not changed from
its qualified state
Requalification: Periodic confirmation to demonstrate that equipment
performance has not changed from its qualified state.

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 220

220

110
9/18/2019

Ongoing Process Control:


Periodic Requalification of Equipment (2)
Include the following:
• Worst case load configuration in requalification
runs
• Review of the following:
– Change control documentation
– Deviations
– Preventative maintenance records
– Routine process data
– Software, set points and control system operations (to
assure no unexpected changes have occurred)
Note: Requalification could also include an empty chamber run to assess
temperature distribution Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 221

221

Ongoing Process Control:


Parametric Release Definition

Parametric Release: A sterility release


system based upon effective control,
monitoring, documentation, and batch
records review of a validated sterilization
process in lieu of release procedures based
on end-product sterility testing, such as,
without having to perform Compendial
sterility testing. This program typically
requires prior regulatory approval

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 222

222

111
9/18/2019

Ongoing Process Control:


Parametric Release (1)
The elements of a parametric release program build on a
foundation of the entire quality system including:

Change Written
Training
control procedures

Planned Failure
Prevention of
preventative mode/risk
human error
maintenance analysis

Product
Validation Calibration release
requirements

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 223

223

Ongoing Process Control:


Parametric Release (2)

• Applies only to products terminally sterilized


in their final containers or packaging
• Regional regulatory approval is required
prior to use
– Once approved for parametric release, a
product cannot be released based on a sterility
test

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 224

224

112
9/18/2019

Ongoing Process Control: (1)


Considerations for Parametric Release
• Quality Risk Management: Risk assessments that
identify risks and take corrective and preventative
measures to mitigate and control those risks to an
acceptable level
• Personnel: Competency in engineering and microbiology
specifically trained in sterilization practices
• Package Integrity Data: Validated container closure
testing after exposure to worst-case sterilization
processing to ensure that the sterilized product maintain its
sterility over the shelf life of the product
• Bioburden Control of pre-sterilized Bioburden: Properly
designed manufacturing facility and processes as well as
an established bioburden monitoring program
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 225

225

Ongoing Process Control: (2)


Considerations for Parametric Release
• Handling Products: Ensure that non-sterile products
are segregated from sterilized product
• Sterilization System: Designed and calibrated to
monitor and control the critical operational parameters
and performance attributes
• Biological Indicators: Well characterized and
appropriately selected to provide worst case
challenge to process
• Physical Parameters: Must be defined, reproducible,
and measurable and should be recorded

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 226

226

113
9/18/2019

Ongoing Process Control: (3)


Considerations for Parametric Release
• Product Specific Approach for Heat Labile Products:
Biorburden should be well-characterized
• Process Development: Includes load definition, load pattern,
and determination of operational parameters. Ensure required
physical and biological lethality are delivered to the product
resulting in the achievement of less than or equal to 10-6 PNSU
• Perform Equipment Qualification and Process Validation
• Ongoing Process Monitoring: Ensures the validated state of
sterilization process
– Load release procedures and criteria
– Requalification and revalidation requirements
– Preventative maintenance
– Change control programs

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 227

227

Review Question #29

When and how often should process


monitoring occur?
A. Every week until product is released
B. On a continuous basis after performance
qualification and release of equipment for
use
C. Once every six months after performance
qualification and release of equipment for
use

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 228

228

114
9/18/2019

Review Question #30

Revalidation is a periodic confirmation to


demonstrate that equipment performance has
not changed from its qualified state.
A. True
B. False

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 229

229

Review Question #31

• A change control program maintains the


state of control and includes the following:
A. Documentation of changes to the
equipment, process, or product
B. Documentation of any testing required
C. Evaluation of equipment, process, and
product changes
D. A and C
E. All of the above
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 230

230

115
9/18/2019

Review Question #32

Parametric release is a sterility release


program for product based on: (select all that
apply)
A. Effective control, monitoring and
documentation of a validated sterility
product manufacturing process
B. Achievement of critical operational
parameters and performance attributes
C. End-product sterility testing
D. A foundation of the entire quality system
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 231

231

Conclusions (1)
• Dry heat processes can provide sterilization or both
depyrogenation and sterilization
– The purpose of the process will dictate the validation
approach
• The dry heat equipment and its support systems
should be designed and constructed to deliver
effective processes in a consistent and reproducible
manner
• The goal of process development is to identify critical
and key operating parameters that will result in a load
meeting the minimum acceptance criteria for
depyrogenation / sterilization
Validation of Dry Heat Processes
© 2013 Parenteral Drug Association 232

232

116
9/18/2019

Conclusions (2)

• Performance qualification is the process of obtaining


and documenting evidence that the equipment, as
installed, consistently operates in accordance with
predetermined criteria
• Ongoing control and monitoring of the process is
conducted on a continuous basis after completion of
performance qualification and release of the equipment
for use

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 233

233

Questions

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 234

234

117
9/18/2019

Thank You

Validation of Dry Heat Processes


© 2013 Parenteral Drug Association 235

235

118

You might also like